This site is intended for healthcare professionals
Drug news

MundiPharma will distribute rezafungin for the treatment and prevention of invasive fungal infections in all markets save for Japan and USA. Cidara Therapeutics

Read time: 1 mins
Last updated:4th Sep 2019
Published:4th Sep 2019
Source: Pharmawand

Cidara Therapeutics, Inc. and Mundipharma announced that they have entered into a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal infections. Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive candidiasis as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation, for which no new therapies have been approved in over 13 years

The partnership agreement follows Cidara�s recent announcement of the successful completion of its STRIVE B Phase II trial. Under the terms of the agreement, in exchange for granting Mundipharma exclusive commercialization rights to rezafungin outside the U.S. and Japan, Cidara will receive a $30 million upfront payment and Mundipharma will make a $9 million equity investment in Cidara. Cidara will also receive an additional $42 million in near-term funding to support the global Phase III ReSTORE and ReSPECT trials for the treatment and prevention of fungal infections. In addition, Cidara is eligible to receive development, regulatory and commercial milestone payments, representing a total potential transaction value of $568 million plus double-digit royalties. Cidara will continue to lead the ongoing global Phase III development programs for rezafungin with the support of Mundipharma. The companies may pursue additional indications or formulations of rezafungin.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.